NCT03078049View on ClinicalTrials.gov

Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Treatment With Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory Data

CompletedOBSERVATIONAL
Enrollment

11,971

Participants

Timeline

Start Date

March 31, 2017

Primary Completion Date

April 30, 2017

Study Completion Date

May 31, 2017

Conditions
Diabetes Mellitus Type 2
Trial Locations (1)

19803

Research Site, Wilmington

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Optum, Inc.

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT03078049 - Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Treatment With Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory Data | Biotech Hunter | Biotech Hunter